Balyasny Asset Management’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Balyasny Asset Management’s Portfolio EFTRW Stock Details EFTRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-200,000	Closed	-$200K	–	2527
2021 Q2	$200K	Buy	200,000 +111,434	+126%	+$90.1K	﹤0.01%	1730
2021 Q1	$54K	Buy	+88,566	New	+$85.5K	﹤0.01%	1681

Other funds holding EFTRW

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Balyasny Asset Management's EFTRW Position: Q3 2021 in Review

Balyasny Asset Management sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q3 2021, closing a stake of 200,000 shares — an estimated $200K sold.

Balyasny Asset Management first reported a position in EFTRW in Q1 2021 and held it in 2 quarters. The position peaked at $200K in Q2 2021. 21 funds tracked by Wall St. Rank hold EFTRW as of Q3 2021.

Balyasny Asset Management reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q3 2021 after selling out during the quarter.
Balyasny Asset Management sold 200,000 eFFECTOR Therapeutics, Inc. Warrant shares in Q3 2021, an estimated $200K.
Balyasny Asset Management first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q1 2021 and held it in 2 quarters.
Balyasny Asset Management's eFFECTOR Therapeutics, Inc. Warrant position peaked at $200K in Q2 2021.
21 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q3 2021.

Based on Balyasny Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.